Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (171-180 of 383) with videos related to

Pageof 39
Sort By:
Clinical Drug Investigation|September 7, 2018
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast CancerGriet Hoste, Laurence Slembrouck, Lynn Jongen, et al.
Journal of Geriatric Oncology|April 25, 2018
Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survivalLisa Speigl, Alexandra Grieb, Nicole Janssen, et al.
Breast Cancer Research and Treatment|November 21, 2018
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutationsLynn Jongen, Giuseppe Floris, Bram Boeckx, et al.
Scientific Reports|December 28, 2022
Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancerHava Izci, Kevin Punie, Lise Waumans, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 27, 2017
Protocol of a randomised controlled trial regarding the effectiveness of fluoroscopy-guided manual lymph drainage for the treatment of breast cancer-related lymphoedema (EFforT-BCRL trial)Tessa De Vrieze, Lore Vos, Nick Gebruers, et al.
Breast Cancer Research and Treatment|May 29, 2015
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patientsChristof Vulsteke, Alena M Pfeil, Charlotte Maggen, et al.
Breast Cancer Research and Treatment|January 7, 2021
Correction to: Behavior of metastatic breast cancer according to subtypeMargot Van Mechelen, Anke Van Herck, Kevin Punie, et al.
Breast Cancer Research and Treatment|March 21, 2020
Behavior of metastatic breast cancer according to subtypeMargot Van Mechelen, Anke Van Herck, Kevin Punie, et al.
The Oncologist|February 12, 2020
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine TherapyPeter A Kaufman, Masakazu Toi, Patrick Neven, et al.
Scientific Reports|February 5, 2021
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancersStijn Moens, Peihua Zhao, Maria Francesca Baietti, et al.
Pageof 39

Showing results (171-180 of 383) with videos related to

Sort By:
Pageof 39
Clinical Drug Investigation|September 7, 2018
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast CancerGriet Hoste, Laurence Slembrouck, Lynn Jongen, et al.
Journal of Geriatric Oncology|April 25, 2018
Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survivalLisa Speigl, Alexandra Grieb, Nicole Janssen, et al.
Breast Cancer Research and Treatment|November 21, 2018
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutationsLynn Jongen, Giuseppe Floris, Bram Boeckx, et al.
Scientific Reports|December 28, 2022
Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancerHava Izci, Kevin Punie, Lise Waumans, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 27, 2017
Protocol of a randomised controlled trial regarding the effectiveness of fluoroscopy-guided manual lymph drainage for the treatment of breast cancer-related lymphoedema (EFforT-BCRL trial)Tessa De Vrieze, Lore Vos, Nick Gebruers, et al.
Breast Cancer Research and Treatment|May 29, 2015
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patientsChristof Vulsteke, Alena M Pfeil, Charlotte Maggen, et al.
Breast Cancer Research and Treatment|January 7, 2021
Correction to: Behavior of metastatic breast cancer according to subtypeMargot Van Mechelen, Anke Van Herck, Kevin Punie, et al.
Breast Cancer Research and Treatment|March 21, 2020
Behavior of metastatic breast cancer according to subtypeMargot Van Mechelen, Anke Van Herck, Kevin Punie, et al.
The Oncologist|February 12, 2020
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine TherapyPeter A Kaufman, Masakazu Toi, Patrick Neven, et al.
Scientific Reports|February 5, 2021
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancersStijn Moens, Peihua Zhao, Maria Francesca Baietti, et al.
Pageof 39